Premium
PharmVar GeneFocus: CYP2C9
Author(s) -
Sangkuhl Katrin,
ClaudioCampos Karla,
Cavallari Larisa H.,
Agundez Jose A.G.,
WhirlCarrillo Michelle,
Duconge Jorge,
Del Tredici Andria L.,
Wadelius Mia,
Rodrigues Botton Mariana,
Woodahl Erica L.,
Scott Stuart A.,
Klein Teri E.,
Pratt Victoria M.,
Daly Ann K.,
Gaedigk Andrea
Publication year - 2021
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.2333
Subject(s) - cyp2c9 , pharmacogenomics , pharmacogenetics , pharmacology , warfarin , allele , medicine , computational biology , biology , bioinformatics , gene , genetics , genotype , atrial fibrillation
The Pharmacogene Variation Consortium (PharmVar) catalogues star (*) allele nomenclature for the polymorphic human CYP2C9 gene. Genetic variation within the CYP2C9 gene locus impacts the metabolism or bioactivation of many clinically important drugs, including nonsteroidal anti‐inflammatory drugs, phenytoin, antidiabetic agents, and angiotensin receptor blockers. Variable CYP2C9 activity is of particular importance regarding efficacy and safety of warfarin and siponimod as indicated in their package inserts. This GeneFocus provides a comprehensive overview and summary of CYP2C9 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase and the Clinical Pharmacogenetics Implementation Consortium.